CSO Neil Bhowmick to deliver company presentation and will be available for investor meetings Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it will participate in the DealFlow Discovery Conference, taking place Jan. 28-29, 2026, at the Borgata Hotel in Atlantic City, NJ. Kairos Pharma Chief Scientific Officer Neil Bhowmick will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Event Details: 3rd Annual DealFlow Discovery Conference The Borgata Hotel, Casino & Spa Atlantic City, NJ Jan. 28-29, 2026 Investors interested in schedul

1/20/26 8:00:00 AM ET

$KAPA

Biotechnology: Pharmaceutical Preparations

Health Care

Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

Company recognized for advancing ENV‑105, a first‑in‑class resistance‑modulating antibody for metastatic castration‑resistant prostate cancer Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it has been selected as a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer. Kairos earned this recognition for its work advancing ENV‑105 (carotuximab), a first‑in‑class CD105‑targeting monoclonal antibody designed to modulate resistance pathways in metastatic castration‑resistant prostate cancer (mCRPC). ENV‑105 is being develop

12/17/25 8:15:00 AM ET

$KAPA

Biotechnology: Pharmaceutical Preparations

Health Care

Kairos Pharma Provides Shareholder Update

Company makes important progress in 2025 and looks ahead into 2026 Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides an overview of key 2025 milestones and outlook into 2026 in a Letter to Shareholders from CEO John Yu, M.D. presented below. To our valued Kairos Pharma Shareholders, This year, Kairos has been focused on executing its Phase 2 randomized clinical trial of ENV105 in combination with apalutamide in patients with advanced metastatic prostate cancer. The study is designed to evaluate the safety, tolerability, and early signs of efficacy of ENV105, a CD105 antagonist, in men whose disease has progre

11/4/25 8:00:00 AM ET

$KAPA

Biotechnology: Pharmaceutical Preparations

Health Care

SEC Form EFFECT filed by Kairos Pharma Ltd.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$KAPA

SEC Form EFFECT filed by Kairos Pharma Ltd.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$KAPA

$KAPA
Press Releases

Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference

Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

Kairos Pharma Provides Shareholder Update

$KAPA
Insider Purchases

VP of Research and Development Murali Ramachandran bought $318 worth of shares (200 units at $1.59), increasing direct ownership by 0.15% to 133,057 units (SEC Form 4)

Chief Financial Officer Samuelson Doug bought $3,750 worth of shares (2,500 units at $1.50), increasing direct ownership by 4% to 60,796 units (SEC Form 4)

CEO and Chairman Yu John S bought $5,760 worth of shares (4,000 units at $1.44), increasing direct ownership by 0.07% to 5,341,837 units (SEC Form 4)

$KAPA
Insider Trading

Chief Scientific Officer Bhowmick Neil was granted 171,756 shares, increasing direct ownership by 15% to 1,311,739 units (SEC Form 4)

Director Bae Hyun W. was granted 29,084 shares, increasing direct ownership by 66% to 73,370 units (SEC Form 4)

VP of Research and Development Murali Ramachandran was granted 152,672 shares, increasing direct ownership by 104% to 299,529 units (SEC Form 4)

$KAPA
SEC Filings